Meeder Asset Management Inc Cue Biopharma, Inc. Transaction History

Meeder Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 02, 2020	SELL	$15.05 - $23.54 $161,561 - $252,701	-10,735 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$12.7 - $30.73 $75,717 - $183,212	5,962 Added 124.91%	10,735 $263,000
Q1 2020 May 15, 2020	BUY	$9.85 - $22.27 $46,846 - $105,916	4,756 Added 27976.47%	4,773 $67,000
Q4 2019 Feb 13, 2020	SELL	$7.06 - $17.47 $4,045 - $10,010	-573 Reduced 97.12%	17 $0
Q3 2019 Oct 17, 2019	BUY	$6.78 - $9.28 $542 - $742	80 Added 15.69%	590 $5,000
Q1 2019 Apr 16, 2019	SELL	$4.7 - $9.29 $1,856 - $3,669	-395 Reduced 43.65%	510 $4,000
Q4 2018 Jan 17, 2019	SELL	$4.35 - $8.73 $4,062 - $8,153	-934 Reduced 50.79%	905 $4,000
Q3 2018 Nov 02, 2018	BUY	$7.91 - $11.89 $14,546 - $21,865	1,839 New	1,839 $0

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.